Chugai Pharma France

What Chugai Pharma France does

Chugai Pharma France SAS is the French commercial subsidiary of Chugai Pharmaceutical Co., Ltd., a Japanese biopharmaceutical company founded in 1925 and majority-owned (59.89%) by Roche since 2002. Established in 1998 and headquartered in Puteaux (La Défense, Paris), the company employs approximately 75 people in France as part of a broader European operation of more than 200 staff across the UK, France, and Germany. Its core activity is the commercialization of three biopharmaceutical products in France across three therapeutic areas: Hemlibra (emicizumab) for hemophilia A, co-promoted with Roche; Granocyte (lenograstim) for neutropenia management in oncology; and RoActemra (tocilizumab) for rheumatology indications. The company operates a sales-led go-to-market model using field-based medical representatives engaging directly with hospital procurement teams, physicians, and retail pharmacies. Products are distributed through direct hospital sales (including tender processes) and retail pharmacy networks, with prices set through French regulatory mechanisms.

The underlying technology base is antibody-based therapeutics and recombinant proteins, with Chugai's parent company maintaining 30+ years of biopharmaceutical expertise since its first biopharma launch in 1990. Chugai Pharma Europe, the regional headquarters in London, houses the European R&D team that contributes to global development programs and leads European clinical trial execution. The company holds continuous Haute Autorité de Santé (HAS) certification for promotional information activities (renewed October 27, 2023) and operates under French pharmaceutical regulatory frameworks. Revenue is generated through pharmaceutical product sales and co-promotion/licensing arrangements with Roche; pricing is regulated and not publicly disclosed.

Chugai Pharma France pursues strategic expansion through innovation partnerships with digital health players (Angels Santé, Digital Pharma Lab, GAIA AG, Zühlke Engineering) and active participation in European healthcare conferences, while exploring digital therapeutics as a new product category. The company maintains CSR programs, pharmacovigilance infrastructure, and compliance functions as part of its regulated pharmaceutical operations.

Name

Chugai Pharma France

Legal name

CHUGAI PHARMA FRANCE SAS

Website

https://chugai.fr

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

51–100 employees

Short description

Chugai Pharma France is the French commercial subsidiary of Chugai Pharmaceutical Co., Ltd. (majority-owned by Roche), commercializing biopharmaceutical products Hemlibra, Granocyte, and RoActemra across hemophilia, oncology, and rheumatology therapeutic areas in France.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oncology & Hematology Pharmaceuticals (HLAIAAAC)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Specialty Injectable & Infusion Therapies (Cross-therapeutic) (HLAIACAO)

Keywords

• Biopharmaceutical products
• Oncology therapeutics
• Hemophilia treatment
• Rheumatology medicines
• Antibody therapeutics

Headquarters

HQ city

Puteaux

HQ country

France

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations

Revenue model

1. Pharmaceutical Product Sales: Chugai Pharma France generates revenue through the sale of innovative biopharmaceutical medicines in France, including Granocyte (lénograstim), Hemlibra (emicizumab) in co-promotion with Roche, and RoActemra (tocilizumab). Products are distributed to hospitals and retail pharmacies.
2. Co-promotion Revenue with Roche: For certain Chugai products licensed to Roche, the companies maintain co-promotion arrangements in Europe, with Chugai Pharma Europe teams collaborating with Roche colleagues to provide co-promoted products to the medical community in France, Germany, and the UK.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Chugai Pharma France commercializes innovative biopharmaceutical medicines in France across three therapeutic areas: hemophilia (Hemlibra®/emicizumab, co-promoted with Roche), oncology and supportive care (Granocyte®/lénograstim), and rheumatology (RoActemra®/tocilizumab). The subsidiary distributes these products to French hospitals and retail pharmacies via medical representatives, manages pharmacovigilance and medical information, and participates in European clinical development led from London.

Product overview

Chugai Pharma France operates as the French subsidiary of Chugai Pharmaceutical Co., Ltd., focusing on the commercialization of innovative medications in France. The product portfolio centers on three therapeutic areas: hemophilia (Hemlibra®), oncology and supportive care (Granocyte®), and rheumatology (RoActemra®). The company also pursues innovation in digital therapeutics and partners with Roche for co-promotion of certain products. Granocyte® (lénograstim) addresses neutropenia in oncology patients; Hemlibra® (emicizumab) provides prophylactic treatment for hemophilia A; RoActemra® (tocilizumab) serves rheumatology patients with its injectable formulations including pre-filled pens and syringes for subcutaneous administration and IV infusion bags.

Differentiator

Problem solved

Functional benefit

Products and services

• Granocyte® 34 Millions UI/ml Poudre et solvant pour solution injectable/perfusion en seringue préremplie containing lénograstim (granulocyte colony-stimulating factor), used for the management of neutropenia, primarily in oncology patients. Marketed in France to hospitals and retail pharmacies.
• Granocyte® 13 Millions UI/ml Poudre et solvant pour solution injectable/perfusion en seringue préremplie containing lénograstim, used for neutropenia management in oncology patients. Marketed in France to hospitals and retail pharmacies.
• Hemlibra® 30 mg/ml Solution injectable containing emicizumab, a bispecific antibody for prophylactic treatment of hemophilia A. Co-promoted in France with strategic partner Roche and distributed to hospitals and retail pharmacies.
• Hemlibra® 150 mg/ml Solution injectable containing emicizumab, a bispecific antibody for prophylactic treatment of hemophilia A. Co-promoted in France with Roche and distributed to hospitals and retail pharmacies.
• RoActemra® 162 mg stylo prérempli Solution injectable en stylo prérempli (pre-filled pen) containing tocilizumab, an anti-IL-6 receptor monoclonal antibody for subcutaneous administration in rheumatology indications.
• RoActemra® 162 mg seringue préremplie Solution injectable en seringue préremplie (pre-filled syringe) containing tocilizumab for subcutaneous administration in rheumatology indications.
• RoActemra® 20 mg/ml Solution à diluer pour perfusion (concentrate for infusion) containing tocilizumab for intravenous administration in rheumatology indications.

Quantifiable outcome

• HAS certification for promotional information activities (renewed October 27, 2023)

Named customers2 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature2 records

Partnerships

Three partnerships are on record, tiered core and minor.

• RochecoreStrategic or Co-development PartnerStrategic alliance established in October 2002 when Roche acquired majority stake (59.89%) in Chugai Pharmaceutical Co., Ltd. Under this alliance, Chugai has exclusive rights to develop and commercialize Roche products in Japan, while Roche can commercialize Chugai products globally. In Europe, co-promotion arrangements exist for certain Chugai products licensed to Roche, with teams collaborating in UK, France, and Germany in hemophilia, oncology, and rheumatology.
• Sanofi S.A.minorStrategic or Co-development PartnerListed as part of Chugai's global network of partners, suggesting collaborative arrangements in the pharmaceutical sector.
• Helsinn Healthcare SAminorStrategic or Co-development PartnerPartnership in oncology supportive care, with Chugai utilizing Helsinn relationships to improve cancer care quality and support patients in Europe.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Ipsen: French-headquartered specialty pharmaceutical company with strong oncology, neuroscience, and rare disease focus. Comparable to Chugai Pharma France as another France-based specialty biopharma operating across similar therapeutic franchises with European commercial scale.
• Daiichi Sankyo France: French subsidiary of Daiichi Sankyo (Japan), another Japanese pharmaceutical company with French commercial operations. Comparable as a peer Japanese pharma affiliate operating specialty biologics and hospital-channel products in France.
• Takeda France: French subsidiary of Takeda Pharmaceutical (Japan), one of Chugai's closest structural analogues as a Japanese-headquartered pharma with French commercial operations. Both operate specialty biologics and rare disease franchises in France through hospital and specialty pharmacy channels.
• UCB France: Belgian specialty biopharmaceutical company with significant French operations focused on immunology and neurology. Comparable to Chugai Pharma France in specialty biologic focus (particularly immunology — overlapping with RoActemra franchise) and hospital/specialty commercial model.
• Eisai France: French subsidiary of Eisai (Japan), a Japanese-headquartered pharma with French operations. Comparable as a Japanese pharma affiliate operating in France with specialty products in oncology and hospital-channel distribution.
• Servier: Major French privately-held pharmaceutical group with oncology, cardiology, and immunology franchises. Directly comparable as a French-based specialty pharmaceutical company with hospital-channel commercial model and European footprint similar to Chugai Pharma France.
• Astellas Pharma France: French subsidiary of Astellas Pharma (Japan), structurally similar to Chugai Pharma France as a Japanese pharma's French commercial affiliate with specialty focus in oncology, hematology, and immunology. Operates comparable hospital-channel distribution model.

Broad incumbents

• Sanofi France: France's largest domestic pharmaceutical company with broad specialty, immunology, oncology, and rare disease portfolios. Comparable as a major French-headquartered pharma with overlapping therapeutic areas (immunology/Rheumatology via Dupixent) and similar hospital/specialty distribution model.
• Novartis France: French subsidiary of Novartis, a global pharmaceutical incumbent with strong specialty and oncology presence. Comparable as a broad incumbent pharma with hospital-channel biologics in oncology, hematology, and rheumatology overlapping with Chugai's therapeutic areas.
• Roche France: French affiliate of the Roche Group — Chugai's strategic alliance partner and majority owner of the parent. Comparable as the dominant oncology and specialty biologics commercial operation in France with extensive hospital-channel reach, and the co-promotion partner for Hemlibra.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/chugai-pharma-france

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chugai Pharma France